At one year, RYGB also produces larger triglyceride decreases, higher HDL-C and apolipoprotein A4, and improvements in hepatic insulin resistance versus diet alone, with parallel reductions in the need for antidiabetic, antihypertensive, and lipid-lowering medications [28]. The gene discussed is APOA4; the disease is Insulin resistance.